Monday , January 25 2021

Patients with NCI-MATCH with AKT1-mutant cancer respond well to AstraZeneca drugs.



  1. AKT1 – NCI-MATCH patients with mutant cancer, respond well to AstraZeneca Drug GenomeWeb
  2. Drug-tailored drugs based on oncologic genetic testing are effective EurekAlert (press release)
  3. All Press


Source link